Abbott Laboratories (ABT) has been identified as one of the best investments during a recession. Bernstein analyst Lee Hambright raised ABT’s price target to $154, anticipating a strong performance in 2026 for healthcare companies like Abbott. However, Goldman Sachs reduced ABT’s price target to $152, citing a return to normalized trends in 2026. Abbott Laboratories is a global healthcare leader with a diversified portfolio, specializing in Continuous Glucose Monitoring (CGM). While ABT offers potential as an investment, consider exploring AI stocks for greater upside potential. No promotional content, just facts presented.

Read more at Yahoo Finance: Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase